ESTRO 2024 - Abstract Book

S2302

Clinical - Urology

ESTRO 2024

Conclusion:

This pilot study using Hydrogel Vue spacer devices in patients receiving prostate SABR with a hypofractionated schedule of 3625cGy in 5 fractions has been encouraging and is consistent with the published data.[4] Long term follow up is required to investigate if the demonstrated dosimetric improvement will correlate with lower rates of late rectal toxicity.

Keywords: Spacer, SABR, Prostate

References:

1 Tan, T.-J., Siva, S., Foroudi, F. and Gill, S. Stereotactic body RT for prostate cancer. Journal of Medical Imaging and Radiation Oncology. 2014, 58: 601-611.

2. Hamstra DA, Mariados N, Sylvester J, Shah D, Karsh L, Hudes R et al. Continued Benefit to Rectal Separation for Prostate Radiation Therapy: Final Results of a Phase III Trial. Int J Radiat Oncol Biol Phys. 2017 Apr 1;97(5):976-985.

3. Montoya J, Gross E, Karsh L. How I Do It: Hydrogel spacer placement in men scheduled to undergo prostate radiotherapy. Can J Urol. 2018 Apr;25(2):9288-9293. PMID: 29680009.

4. Armstrong N, Bahl A, Pinkawa M, Ryder S, Ahmadu C, Ross J, et al. SpaceOAR Hydrogel Spacer for Reducing Radiation Toxicity During Radiotherapy for Prostate Cancer. A Systematic Review. Urology. 2021 Oct;156:e74-e85.

236

Digital Poster

Cox regression may indicate candidates for radiotherapy with boost after prostatectomy.

HISATO NAGANO 1 , Hiroko Yokoyama 1 , Masahiro Kato 2 , Harumitu Hashimoto 1 , Takahiro Shimo 3 , Motoi Watanabe 1 , Masanori Nakanishi 1 , Hiroshi Suzuki 1 , Yuichi YuichiKaneko 1 , Satoko Tanaka 1 , Yu Goto 1 , Masafumi Notani 1 , Saeri Nakamura 1 , Erika Namiki 1 , Saeri Nakamura 1 1 Shonan fujisawa tokushukai Hp., Radiotherapy, Fujisawa, Japan. 2 Tokyo-west tokushukai Hp., Radiotherapy, Akishima, Japan. 3 Shonan kamakura general Hp., Radiotherapy, Kamakura, Japan

Purpose/Objective:

This is a retrospective biochemical failure analysis of post-prostatectomy cases who received adjuvant radiotherapy with or without boost irradiation for prostate cancer. Cox proportional hazards model was used to calculate hazard ratios for preoperative status, pathological findings, and radiation dose. The recommended prescribed doses for